secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001171843-26-000213
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst beats FY2025 ORLADEYO rev guidance; FY2026 outlook $625-645M; Astria acquisition on track
--------------------------------------------------------------------------------

- Preliminary unaudited FY2025 ORLADEYO net revenue $601M (+37% YoY), exceeding $590-600M guidance range.
- Q4 2025 ORLADEYO net revenue $151M (+22% YoY; +36% comparable basis excl European revenue).
- Cash, cash equivalents, restricted cash & investments at Dec 31, 2025: $338M.
- FY2026 guidance: ORLADEYO rev $625-645M; total rev $635-660M; non-GAAP op ex $380-390M (excl Astria).
- Expected close of Astria Therapeutics acquisition in Q1 2026; adds $70-80M non-GAAP op ex for navenibart Phase 3 and manufacturing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326000213/0001171843-26-000213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326000213/f8k_011226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-000213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer